ACADIA Pharmaceuticals, Inc. Announces Publication in The Lancet of Pivotal Phase III Parkinson's Disease Psychosis Trial With Pimavanserin
Published: Nov 01, 2013
SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced the publication of data from its pivotal Phase III -020 Study with pimavanserin in patients with Parkinson’s disease psychosis (PDP) in the November 1, 2013 online issue of The Lancet. In the -020 Study, pimavanserin demonstrated significant and clinically meaningful benefits and was safe and well tolerated in patients with PDP. Pimavanserin significantly reduced psychosis and maintained motor control in patients with PDP. Significant benefits were also observed in exploratory measures of nighttime sleep, daytime wakefulness and caregiver burden.
Help employers find you! Check out all the jobs and post your resume.